$EPIX
ESSA Pharma Inc.

2021 Q3 Form 10-Q Financial Statement

#000155837021011748 Filed on August 16, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $2.947M $3.122M $2.140M
YoY Change 38.33% 45.88% 73.98%
% of Gross Profit
Research & Development $6.273M $6.232M $2.704M
YoY Change 189.08% 130.5% 40.09%
% of Gross Profit
Depreciation & Amortization $100.0K
YoY Change
% of Gross Profit
Operating Expenses $9.220M $9.366M $5.072M
YoY Change 108.12% 84.68% 60.5%
Operating Profit -$5.072M
YoY Change 60.5%
Interest Expense $660.1K $602.6K -$60.00K
YoY Change -607.74% -1104.35% -50.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$8.560M -$8.751M -$4.925M
YoY Change 87.71% 77.7% 49.69%
Income Tax $0.00 $800.00 $0.00
% Of Pretax Income
Net Earnings -$8.560M -$8.752M -$4.925M
YoY Change 88.12% 77.71% 49.24%
Net Earnings / Revenue
Basic Earnings Per Share -$0.21
Diluted Earnings Per Share -$198.5K -$0.21 -$236.8K
COMMON SHARES
Basic Shares Outstanding 43.98M 41.02M
Diluted Shares Outstanding 41.02M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $194.9M $202.3M $36.50M
YoY Change 148.95% 454.15% 644.9%
Cash & Equivalents $137.8M $145.2M $36.48M
Short-Term Investments $57.10M $57.07M
Other Short-Term Assets $2.182M $463.8K $900.0K
YoY Change 28.35% -48.47% 350.0%
Inventory
Prepaid Expenses $2.182M $463.8K
Receivables $489.0K $231.2K $300.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $197.6M $203.0M $37.70M
YoY Change 146.08% 438.35% 611.32%
LONG-TERM ASSETS
Property, Plant & Equipment $308.3K $297.5K $100.0K
YoY Change 197.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $259.5K $268.6K $300.0K
YoY Change -13.51% -10.48% -80.0%
Total Long-Term Assets $567.7K $566.1K $600.0K
YoY Change 104.49% -5.65% -66.67%
TOTAL ASSETS
Total Short-Term Assets $197.6M $203.0M $37.70M
Total Long-Term Assets $567.7K $566.1K $600.0K
Total Assets $198.2M $203.5M $38.30M
YoY Change 145.94% 431.39% 439.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.426M $907.5K $1.200M
YoY Change 110.11% -24.37% -42.86%
Accrued Expenses $2.062M $1.703M $100.0K
YoY Change 564.01% 1602.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change -100.0%
Total Short-Term Liabilities $3.930M $3.009M $1.300M
YoY Change 226.57% 131.44% -74.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $230.6K $817.7K $100.0K
YoY Change 130.6% 717.74%
Total Long-Term Liabilities $230.6K $817.7K $100.0K
YoY Change 130.6% 717.74% -92.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.930M $3.009M $1.300M
Total Long-Term Liabilities $230.6K $817.7K $100.0K
Total Liabilities $4.160M $3.826M $1.400M
YoY Change 212.64% 173.32% -78.46%
SHAREHOLDERS EQUITY
Retained Earnings -$117.8M -$109.2M
YoY Change 45.46%
Common Stock $277.4M $277.4M
YoY Change 111.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $194.0M $199.7M $36.76M
YoY Change
Total Liabilities & Shareholders Equity $198.2M $203.5M $38.30M
YoY Change 145.94% 431.39% 439.44%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$8.560M -$8.752M -$4.925M
YoY Change 88.12% 77.71% 49.24%
Depreciation, Depletion And Amortization $100.0K
YoY Change
Cash From Operating Activities -$7.383M -$6.512M -$3.210M
YoY Change 66.67% 102.88% 28.92%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$14.77K $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 -$14.77K $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.32K 187.4K -220.0K
YoY Change -99.97% -185.2% -84.62%
NET CHANGE
Cash From Operating Activities -7.383M -6.512M -3.210M
Cash From Investing Activities 0.000 -14.77K 0.000
Cash From Financing Activities 13.32K 187.4K -220.0K
Net Change In Cash -7.370M -6.340M -3.430M
YoY Change -137.07% 84.83% -7.8%
FREE CASH FLOW
Cash From Operating Activities -$7.383M -$6.512M -$3.210M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001633932
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41854916
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32064411
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37410
dei Entity Registrant Name
EntityRegistrantName
ESSA Pharma Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
dei Entity Address Country
EntityAddressCountry
CA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2569713
dei Entity Address Address Line1
EntityAddressAddressLine1
Suite 720
dei Entity Address Address Line2
EntityAddressAddressLine2
999 West Broadway
dei Entity Address City Or Town
EntityAddressCityOrTown
Vancouver
dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V5Z 1K5
dei City Area Code
CityAreaCode
778
dei Local Phone Number
LocalPhoneNumber
331-0962
dei Security12b Title
Security12bTitle
Common Shares
dei Trading Symbol
TradingSymbol
EPIX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43984346
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1600128
CY2021Q2 epix Operating Lease Right Of Use Assets Current
OperatingLeaseRightOfUseAssetsCurrent
0
CY2020Q3 epix Operating Lease Right Of Use Assets Current
OperatingLeaseRightOfUseAssetsCurrent
55162
CY2021Q2 us-gaap Assets Current
AssetsCurrent
202957938
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
145194181
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56320763
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
57068822
CY2020Q3 us-gaap Short Term Investments
ShortTermInvestments
22011337
CY2021Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
231146
CY2020Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
309538
CY2021Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
463789
CY2020Q3 us-gaap Assets Current
AssetsCurrent
80296928
CY2021Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
268574
CY2020Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
277637
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
297533
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2021Q2 us-gaap Assets
Assets
203524045
CY2020Q3 us-gaap Assets
Assets
80574565
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2910964
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1144230
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
97763
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
59094
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3008727
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1203324
CY2021Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
597508
CY2020Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
127376
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
220227
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q2 us-gaap Liabilities
Liabilities
3826462
CY2020Q3 us-gaap Liabilities
Liabilities
1330700
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41854916
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32064411
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
277370996
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
131086364
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
33619332
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
31204284
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2076479
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2076479
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109216266
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80970304
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
199697583
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
79243865
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
203524045
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
80574565
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6231908
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2703704
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17985937
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9909288
CY2021Q2 epix Financing Costs
FinancingCosts
16667
CY2020Q2 epix Financing Costs
FinancingCosts
197102
epix Financing Costs
FinancingCosts
18147
epix Financing Costs
FinancingCosts
500972
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3117900
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2171020
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9942149
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9173793
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
9366475
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
5071826
us-gaap Operating Expenses
OperatingExpenses
27946233
us-gaap Operating Expenses
OperatingExpenses
19584053
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-34084
CY2020Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
10937
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-19239
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-685
CY2021Q2 us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
80394
CY2020Q2 us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
172346
us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
155293
us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
478952
CY2021Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
568954
CY2020Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-36285
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-470132
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-60242
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8751211
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4924828
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28280311
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19166028
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-34349
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-274000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8752011
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4924828
us-gaap Net Income Loss
NetIncomeLoss
-28245962
us-gaap Net Income Loss
NetIncomeLoss
-18892028
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.91
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41018024
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20824568
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36937014
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20802026
us-gaap Net Income Loss
NetIncomeLoss
-28245962
us-gaap Net Income Loss
NetIncomeLoss
-18892028
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
80665
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
82743
us-gaap Accretion Expense
AccretionExpense
5497
us-gaap Accretion Expense
AccretionExpense
10893
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-470132
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-60242
epix Interest Income Operating Activities
InterestIncomeOperatingActivities
42719
epix Interest Income Operating Activities
InterestIncomeOperatingActivities
0
epix Finance Expense Operating Activities
FinanceExpenseOperatingActivities
0
epix Finance Expense Operating Activities
FinanceExpenseOperatingActivities
211079
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-26497
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-15396
us-gaap Share Based Compensation
ShareBasedCompensation
6652613
us-gaap Share Based Compensation
ShareBasedCompensation
6347186
epix Income Tax Expense Recovery Operating Activities
IncomeTaxExpenseRecoveryOperatingActivities
0
epix Income Tax Expense Recovery Operating Activities
IncomeTaxExpenseRecoveryOperatingActivities
278000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
57026103
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
22000000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
0
epix Interest From Short Term Investments
InterestFromShortTermInvestments
11337
epix Interest From Short Term Investments
InterestFromShortTermInvestments
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35014766
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18032326
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12832170
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-104749
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-12971
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1145402
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
297467
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1770800
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-83185
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
0
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-22000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
149999985
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
9229451
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
314603
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1186833
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
915
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
382
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
247864
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
89318
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
80714
epix Operating Lease Payments Financing Activities
OperatingLeasePaymentsFinancingActivities
69637
epix Operating Lease Payments Financing Activities
OperatingLeasePaymentsFinancingActivities
89096
us-gaap Repayments Of Debt
RepaymentsOfDebt
0
us-gaap Repayments Of Debt
RepaymentsOfDebt
3199799
epix Repayments Of Final Payment Of Debt
RepaymentsOfFinalPaymentOfDebt
0
epix Repayments Of Final Payment Of Debt
RepaymentsOfFinalPaymentOfDebt
688000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
32235
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
141977430
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3994240
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-56920
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-14264
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
88873418
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16840674
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56320763
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53322723
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
145194181
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36482049
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
48981829
CY2019Q4 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
10652
CY2019Q4 epix Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
227864
CY2019Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1253621
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-9353927
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
40090079
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-4613273
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
45839389
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3584617
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
915
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
80714
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1508948
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4924828
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
36755828
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
79243865
CY2020Q4 epix Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
149
CY2020Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
153701
CY2020Q4 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
27369
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1204985
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-6528704
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
74101365
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
149999985
CY2021Q1 epix Stock Issued During Period Issuance Cost
StockIssuedDuringPeriodIssuanceCost
9168801
CY2021Q1 epix Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
100
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
776985
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2663684
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-12965247
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
205408071
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
60649
CY2021Q2 epix Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
133
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
256147
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
61948
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2783944
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8752011
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
199697583
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.     NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Nature of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company was incorporated under the laws of the Province of British Columbia on January 6, 2009. The Company’s head office address is Suite 720 – 999 West Broadway, Vancouver, BC, V5Z 1K5. The registered and records office address is the 26<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> Floor at 595 Burrard Street, Three Bentall Centre, Vancouver, BC, V7X 1L3. The Company is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “EPIX”. On October 30, 2020 the Company’s common shares delisted in Canada from the TSX Venture Exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is focused on the development of small molecule drugs for the treatment of prostate cancer. The Company has acquired a license to certain patents (“NTD”) which were the joint property of the British Columbia Cancer Agency and the University of British Columbia. As of June 30, 2021, no products are in commercial production or use.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of the accompanying condensed consolidated interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as of the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liabilities, the valuation of equity instruments issued for services, income taxes and the product development and relocation grant. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only, or in the period of the change and future periods, if the change affects both. Estimates and assumptions are reviewed quarterly.</p>
CY2021Q2 us-gaap Prepaid Insurance
PrepaidInsurance
149179
CY2020Q3 us-gaap Prepaid Insurance
PrepaidInsurance
825014
CY2021Q2 epix Prepaid Preclinical And Clinical Expenses And Deposits
PrepaidPreclinicalAndClinicalExpensesAndDeposits
126000
CY2020Q3 epix Prepaid Preclinical And Clinical Expenses And Deposits
PrepaidPreclinicalAndClinicalExpensesAndDeposits
650586
CY2021Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
188610
CY2020Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
124528
CY2021Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
463789
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1600128
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
907537
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
678643
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1702793
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
310604
CY2021Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
300634
CY2020Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
154983
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2910964
CY2020Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1144230
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
82743
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
82743
CY2020Q3 epix Operating Lease Right Of Use Assets Current
OperatingLeaseRightOfUseAssetsCurrent
55162
epix Operating Lease Right Of Use Asset Addition
OperatingLeaseRightOfUseAssetAddition
323036
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
80665
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
297533
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
0
epix Operating Lease Liabilities Accretion Expenses
OperatingLeaseLiabilitiesAccretionExpenses
10893
us-gaap Operating Lease Payments
OperatingLeasePayments
89096
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
87283
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
59094
epix Operating Lease Liabilities Addition
OperatingLeaseLiabilitiesAddition
323036
epix Operating Lease Liabilities Accretion Expenses
OperatingLeaseLiabilitiesAccretionExpenses
5497
us-gaap Operating Lease Payments
OperatingLeasePayments
69637
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
317990
CY2021Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.050
CY2021Q2 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P38M
CY2019Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
16520
CY2020 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-110856
CY2020Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
127376
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-470132
CY2021Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
597508
CY2021Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2021Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
597508
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1122461
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.59
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4218000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.31
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
416
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.20
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
30461
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
28.46
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5309584
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1889646
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.87
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
323610
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
72390
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
4.46
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6803230
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.20
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2496961
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.50
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6803230
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1889646
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4218000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.87
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.31
CY2019Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12393092
CY2019Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.31
CY2020 epix Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
3120115
CY2020 epix Class Of Warrant Or Right Weighted Average Exercise Price Warrants Exercised
ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised
-0.08
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9272977
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.73
epix Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
3913227
epix Class Of Warrant Or Right Weighted Average Exercise Price Warrants Exercised
ClassOfWarrantOrRightWeightedAverageExercisePriceWarrantsExercised
-0.10
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5359750
CY2021Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.92
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5359750
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q2 epix Working Capital
WorkingCapital
199949211

Files In Submission

Name View Source Status
0001558370-21-011748-index-headers.html Edgar Link pending
0001558370-21-011748-index.html Edgar Link pending
0001558370-21-011748.txt Edgar Link pending
0001558370-21-011748-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20210630.xsd Edgar Link pending
tmb-20210630x10q.htm Edgar Link pending
tmb-20210630x10q001.jpg Edgar Link pending
tmb-20210630x10q_htm.xml Edgar Link completed
tmb-20210630xex31d1.htm Edgar Link pending
tmb-20210630xex31d2.htm Edgar Link pending
tmb-20210630xex32d1.htm Edgar Link pending
tmb-20210630_cal.xml Edgar Link unprocessable
tmb-20210630_def.xml Edgar Link unprocessable
tmb-20210630_lab.xml Edgar Link unprocessable
tmb-20210630_pre.xml Edgar Link unprocessable